Cardiovascular

Cytokinetics receives FDA approval for MYQORZO tablets for oHCM

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to enhance functional capacity and symptoms.

FDA expands Amgen’s Repatha use to adults at risk of cardiovascular events

The US Food and Drug Administration (FDA) has expanded the use of Amgen’s Repatha (evolocumab) to include adults who are at high risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C).

Camurus and Eli Lilly collaborate on long-acting incretin products

Camurus and Eli Lilly have signed a partnership and license agreement focused on long-acting incretin products to improve cardiometabolic health.

Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders

Sirius Therapeutics has secured around $50m in a Series B2 funding round for the clinical development of small interfering RNA (siRNA) therapeutics targeting cardiometabolic disorders.

Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial

Imbria Pharmaceuticals has secured $57.5m in a Series B funding round to support the progression of ninerafaxstat through a double-blind Phase IIb FORTITUDE-HCM trial in non-obstructive hypertrophic cardiomyopathy (nHCM).

BridgeBio’s Beyonttra gains approval in Japan for ATTR-CM treatment

BridgeBio Pharma has received the Japanese Ministry of Health, Labour and Welfare approval for Beyonttra, a brand name for acoramidis, for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

FDA accepts Alnylam’s vutrisiran sNDA to treat ATTR-CM

The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) of Alnylam Pharmaceuticals’ vutrisiran for review.

AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy

AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.

FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction

The US Food and Drug Administration (FDA) has granted approval for Novo Nordisk's Wegovy (semaglutide 2.4 mg) for lowering cardiovascular risks in adults with established cardiovascular disease (CVD) who are overweight or obese.